Workplace saliva drug tests in France: 4 rules and CBD
Yes. A French employer can have a saliva drug test carried out, even by a line manager, provided that all four conditions set in 2016 by the Conseil d'État (France's highest administrative court) are met. The test detects THC and ignores CBD. A legally sold CBD product, with no more than 0.3% THC, can therefore be enough to turn it positive.
Key takeaways
- Testing has to be set out in the company's internal rules and confined to posts where drug impairment is particularly dangerous.
- If you test positive, you can get a medical counter-test at the employer's expense, and the result is protected by professional secrecy.
- The saliva device detects Δ⁹-THC. The 0.3% threshold limits the THC in a product and does not mean the product has none.
- In enclosed, covered shared workplaces, smoking and vaping are banned, with or without CBD.
What the Conseil d'État ruled on 5 December 2016
The dispute started with the internal rules of a public works company, which let line managers carry out random saliva tests on staff holding posts classed as "hypersensitive to drugs and alcohol". The labour inspectorate contested the clause on the ground that taking a saliva sample was a medical act.
The Conseil d'État found for the company. In decision no. 394178, it held that an on-the-spot saliva test is not a medical laboratory examination, since its sole purpose is to reveal recent use. As a result, no rule restricts it to a doctor or a biologist.
People often reduce the ruling to "the employer can test", which leaves out most of it. The court approved one specific clause, hedged with safeguards, and a test that departs from it is outside the approved framework.
The 4 conditions for a lawful saliva test
INRS, France's national occupational safety institute, sums up the four conditions that follow from the ruling. All four must be met, and if even one is missing, the test can be challenged.
| Condition | What it requires in practice |
|---|---|
| Internal rules | The test is written in, with the list of posts concerned and the practical arrangements. |
| Safety-critical post | Drug impairment creates a particularly high danger for the employee or others. Testing is not blanket. |
| Counter-test | An employee who tests positive can request a medical counter-test, paid for by the employer. |
| Professional secrecy | The employer or manager running the test does not disclose the result. |
Posts are classed as safety-critical case by case. Typical examples involve driving vehicles or operating machinery, working at height or handling hazardous substances. In principle, an office job with no particular risk is outside this category.
The internal rules are the cornerstone
Article L1321-1 of the French Labour Code states that internal rules contain "exclusively" three sets of provisions, the first being health and safety measures. A testing clause has its place there only because it serves safety.
Companies with at least fifty employees must have internal rules, under article L1311-2, and drafting them follows a set procedure. Article L1321-4 requires the text to go to the works council (CSE) for an opinion and then to the labour inspector. It takes effect at least one month after publication. For drug testing, a simple staff memo falls short of these requirements.
The clause must also pass the proportionality test of article L1121-1: any restriction of freedoms has to be justified by the nature of the task and proportionate to its aim. This article is what rules out, for instance, testing the entire workforce whatever their post.
Why legal CBD can make the test positive
Cannabidiol is not what the saliva test looks for. As Drogues Info Service, the information service of Santé publique France, points out, the device reacts to Δ⁹-THC. A CBD user who tests positive was using a product that contained THC.
The 0.3% threshold is a maximum. A flower or resin at 0.2% THC contains some THC, and smoking or vaporising it brings that THC into the saliva. The same source says a compliant product stays detectable in saliva for at least three hours. Our guide to CBD and drug screening compares saliva, urine and blood tests, and the detection windows are in our article on how long CBD stays in the body.
Two caveats on method. The Drogues Info Service page is about roadside checks, and we found no official data on how sensitive the kits used in workplaces are. Separately, in an alert dated 19 June 2025, France's medicines agency ANSM and food safety agency Anses advise machine operators and road users against CBD because of a risk of drowsiness. Those are the very posts a testing clause targets.
An employee in a safety-critical post who wants to reduce the risk can opt for a THC-free oil and check the batch's certificate of analysis to confirm that THC is not detected. Flowers and resins always contain a small amount of THC.
Can you smoke or vape CBD at work?
Not indoors. According to the French labour ministry, the ban on smoking and vaping covers enclosed, covered workplaces used collectively. Since the rule is about the act of smoking, a CBD flower joint falls under it exactly as a cigarette does. The only exemption is for smoking rooms built to technical standards.
Outdoors or during a break, no specific law prohibits using a legal CBD product, although the internal rules may regulate behaviour that bears on safety. In a safety-critical post the risk stays the same: residual THC that a test can pick up.
Roadside and workplace testing: two regimes
The saliva tests are similar in both settings, yet the law that governs them differs, as the table shows.
| Roadside check | Workplace check | |
|---|---|---|
| Who tests | Police | Employer or manager, if the internal rules provide for it |
| Who can be tested | Any driver | Employees in a safety-critical post |
| Refusing the test | Offence: 3 years in prison and a 9,000 € fine | Not an offence, but possible disciplinary fault |
| Positive result | Criminal prosecution, whatever the dose | Possible disciplinary action, counter-test as of right |
For driving, France's Court of Cassation ruled on 21 June 2023 that the permission to sell hemp products under 0.30% THC has no bearing on the offence of driving after drug use. The offence applies at any dose, because the regulatory threshold is a detection threshold and has no criminal meaning. The penalties for driving after drug use and for refusing the checks, set in articles L235-1 and L235-3 of the Highway Code, are three years in prison and a 9,000 € fine. Our article on CBD and driving covers this regime.
Employment law has its own proportionality rules, so this criminal case law cannot be transposed to it unchanged. It still shows how judges reason: buying a legal product does not erase the presence of the substance the test looks for. Our comparison of THC and CBD explains how the two molecules differ.
Frequently asked questions
Yes, provided four conditions are met. The test must be set out in the internal rules and target a post where drug impairment creates a particularly high danger. It must also give you the right to a medical counter-test paid by the employer, and the result must stay confidential. A test outside that framework can be challenged.
No. The test reacts to Δ⁹-THC. When a CBD user tests positive, the cause is the THC in the product, even at legal levels; cannabidiol plays no part.
At work, refusing is not an offence, whereas at the roadside it is. If the internal rules properly provide for the test for your post, however, a refusal can count as a disciplinary fault. After a positive result, you keep the right to a medical counter-test.
Lawful use in your private life is not misconduct in itself, since article L1121-1 limits restrictions to what the task justifies. A positive result in a safety-critical post, within the lawful framework described above, does raise a safety question. For your own situation, ask the occupational doctor or an employment lawyer.
No. INRS insists that testing be confined to safety-critical posts and never be systematic. Under article L1121-1, testing every employee without regard to the risks of their post would be disproportionate.
Written by the Phytogrammes team
Each journal article draws on cited primary sources: ANSM, EFSA, EUR-Lex and peer-reviewed publications. Product profiles are distinguished from documented laboratory results. Our approach.
Article published on . CBD is not a medicine.